ADAM-17: a target to increase chemotherapeutic efficacy in colorectal cancer?

Clin Cancer Res. 2010 Jul 1;16(13):3319-21. doi: 10.1158/1078-0432.CCR-10-1059. Epub 2010 Jun 22.

Abstract

Chemotherapy-induced activation of ADAM-17 results in increased growth factor shedding and activation of growth factor receptor-mediated pro-survival response. Enhanced ADAM-17 activity and HER ligand shedding results in resistance to chemotherapy in CRC. Therapies that decrease ADAM-17 activity in conjunction with current treatments may enhance response rates in advanced CRC patients.

Publication types

  • Comment

MeSH terms

  • ADAM Proteins / antagonists & inhibitors*
  • ADAM Proteins / metabolism
  • ADAM17 Protein
  • Biomarkers, Tumor / antagonists & inhibitors
  • Biomarkers, Tumor / metabolism
  • Colorectal Neoplasms / drug therapy*
  • Drug Delivery Systems
  • Drug Resistance, Neoplasm
  • ErbB Receptors / metabolism
  • Humans

Substances

  • Biomarkers, Tumor
  • ErbB Receptors
  • ADAM Proteins
  • ADAM17 Protein
  • ADAM17 protein, human